Integrated Quantitative Investments LLC Invests $254,000 in Pro-Dex, Inc. (NASDAQ:PDEX)

Integrated Quantitative Investments LLC bought a new stake in shares of Pro-Dex, Inc. (NASDAQ:PDEX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,432 shares of the medical instruments supplier’s stock, valued at approximately $254,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of PDEX. Ritholtz Wealth Management bought a new position in shares of Pro-Dex during the 4th quarter valued at about $572,000. FMR LLC lifted its position in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares in the last quarter. Geode Capital Management LLC boosted its stake in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Pro-Dex during the 4th quarter valued at approximately $202,000. Finally, JPMorgan Chase & Co. increased its stake in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

Insider Buying and Selling at Pro-Dex

In related news, Director Raymond E. Cabillot sold 1,200 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $47.76, for a total transaction of $57,312.00. Following the transaction, the director now directly owns 359,646 shares in the company, valued at approximately $17,176,692.96. This represents a 0.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 49,153 shares of company stock worth $2,270,494 over the last quarter. Insiders own 47.50% of the company’s stock.

Pro-Dex Stock Up 0.5 %

Shares of NASDAQ:PDEX opened at $50.90 on Friday. The company has a 50-day moving average price of $41.10 and a 200 day moving average price of $40.87. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. Pro-Dex, Inc. has a 12 month low of $16.84 and a 12 month high of $59.60. The company has a market cap of $165.98 million, a price-to-earnings ratio of 25.32 and a beta of 0.40.

Pro-Dex (NASDAQ:PDEX) last announced its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities research analysts predict that Pro-Dex, Inc. will post 2 earnings per share for the current year.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.